Search results for "pulmonary"

showing 10 items of 3030 documents

Shear Stress and Aortic Strain Associations With Biomarkers of Ascending Thoracic Aortic Aneurysm

2019

This study aims to investigate the association of wall shear stress (WSS) and aortic strain with circulating biomarkers including matrix metalloproteinases (MMP), tissue inhibitors of metalloproteinase (TIMP), and exosomal level of microRNA (miRNA) in ascending aortic aneurysms of patients with bicuspid or tricuspid aortic valve.A total of 76 variables from 125 patients with ascending aortic aneurysms were collected from (1) blood plasma to measure plasma levels of miRNAs and protein activity; (2) computational flow analysis to estimate peak systolic WSS and time-average WSS (TAWSS); and (3) imaging analysis of computed tomography angiography to determine aortic wall strain. Principal compo…

AdultMalePulmonary and Respiratory MedicineAortic valvemedicine.medical_specialtybicuspid aortic valveVascular Remodeling030204 cardiovascular system & hematologyMechanotransduction CellularThoracic aortic aneurysm03 medical and health sciencesAortic aneurysm0302 clinical medicineBicuspid aortic valveBicuspid Aortic Valve Diseaseascending thoracic aortic aneurysmMatrix Metalloproteinase 12medicine.arteryInternal medicineAscending aortamedicineHumansAortaAgedComputed tomography angiographyAortaTissue Inhibitor of Metalloproteinase-1Aortic Aneurysm Thoracicmedicine.diagnostic_testbusiness.industrybiomarkersSettore ING-IND/34 - Bioingegneria IndustrialeMiddle Agedmedicine.diseaseMicroRNAsLogistic ModelsBlood pressuremedicine.anatomical_structure030228 respiratory systemAortic Valvecardiovascular systemCardiologyFemaleSurgeryStress MechanicalMatrix Metalloproteinase 1Cardiology and Cardiovascular MedicinebusinessThe Annals of Thoracic Surgery
researchProduct

Baroreflex control of heart rate during sleep in severe obstructive sleep apnoea: effects of acute CPAP

2006

Baroreflex control of heart rate during sleep (baroreflex sensitivity; BRS) has been shown to be depressed in obstructive sleep apnoea (OSA), and improved after treatment with continuous positive airway pressure (CPAP). Whether CPAP also acutely affects BRS during sleep in uncomplicated severe OSA is still debatable. Blood pressure was monitored during nocturnal polysomnography in 18 patients at baseline and during first-time CPAP application. Spontaneous BRS was analysed by the sequence method, and estimated as the mean sequence slope. CPAP did not acutely affect mean blood pressure or heart rate but decreased cardiovascular variability during sleep. Mean BRS increased slightly during CPAP…

AdultMalePulmonary and Respiratory MedicineBaroreceptorPolysomnographymedicine.medical_treatmentPositive pressureBaroreflexHeart RateHeart rateHumansMedicineContinuous positive airway pressureMechanical ventilationAnalysis of VarianceSleep Apnea ObstructiveContinuous Positive Airway Pressurebusiness.industryBaroreflexMiddle Agedrespiratory tract diseasesMean blood pressureBlood pressurebaroreceptors blood pressure hypoxia positive intrathoracic pressure sleepAnesthesiaLinear ModelsMED/09 - MEDICINA INTERNAbusinesscirculatory and respiratory physiologyEuropean Respiratory Journal
researchProduct

Clinical and anti-inflammatory effects of ultra-short preseasonal vaccine to Parietaria in asthma

2013

Objective: The ultra-short course preseasonal allergy vaccine, containing the adjuvant monophosphoryl lipid A (MPL), is effective in treating allergic symptoms; however, the efficacy in controlling asthmatics symptoms has not been fully demonstrated. We aimed at evaluating whether the ultra-short preseasonal course of immunotherapy contributes to asthma control. Methods: Four subcutaneous injections of the active product (Pollinex Quattro) were administered, before the pollen season, to 20 Parietaria-sensitive mild, untreated asthmatics (M/F: 12/8; age: 38 ± 14 years). After the screening visit (visit 1), asthma control was assessed by the Asthma Control Test (ACT) immediately before the fi…

AdultMalePulmonary and Respiratory MedicineBreath TestParietariamedicine.drug_classmedicine.medical_treatmentMonophosphoryl Lipid Aairway inflammationSettore MED/10 - Malattie Dell'Apparato RespiratorioNitric OxideAnti-inflammatoryAllergic symptomsmedicineHumansPharmacology (medical)LungAsthmaInflammationVaccinesbiologybusiness.industryAllergy vaccineImmunotherapyMiddle Agedmedicine.diseasebiology.organism_classificationAsthmaParietariaquality of lifeBreath TestsDesensitization ImmunologicImmunologyFemaleimmunotherapybusinessVaccineAdjuvantHumanTherapeutic Advances in Respiratory Disease
researchProduct

Comparing asthma treatment in elderly versus younger patients

2011

SummaryA randomised 6-month study compared two maintenance doses of budesonide/formoterol (Symbicort® Turbuhaler®)hhNeither the Symbicort SMART posology nor the dry powder formulation, Turbuhaler, is currently approved in the US. maintenance and reliever therapy (Symbicort SMART®), 160/4.5 μg 1 × 2 and 2 × 2, in 8053 asthmatics with symptoms despite treatment with inhaled corticosteroids ± inhaled long-acting β2-agonists. This analysis compared response to the two treatments in elderly patients, ≥65 years, with that in younger patients. Elderly patients with early- or late-onset asthma were also compared.Elderly patients had lower post-bronchodilator FEV1 percentage predicted normal at base…

AdultMalePulmonary and Respiratory MedicineBudesonideSymbicort SMARTmedicine.medical_specialtylaw.inventionExacerbationsElderlyRandomized controlled triallawFormoterol FumarateSurveys and QuestionnairesInternal medicineAdministration InhalationmedicineHumansBudesonideBudesonide/formoterolAgedAsthmaACQDose-Response Relationship Drugbusiness.industryHazard ratiomedicine.diseaseConfidence intervalAsthmaBronchodilator AgentsSurgeryTreatment OutcomeBudesonide/formoterolEthanolaminesAsthma Control QuestionnaireDisease ProgressionQuality of LifeDrug Therapy CombinationFemaleFormoterolbusinessmedicine.drugRespiratory Medicine
researchProduct

Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed mai…

2004

Asthma guidelines suggest a stepwise approach to maintenance pharmacological treatment of persistent asthma until control is attained, and a 3 month review of the fixed maintenance dosing for step-up or step-down adjustment. This 12-week study compared the efficacy and safety of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler 160/4.5 or 80/4.5 microg) given as adjustable maintenance or fixed maintenance dosing. Patients (n = 2358) were randomised to budesonide/formoterol fixed maintenance dosing (two inhalations bid) or adjustable maintenance dosing (two inhalation bid; stepping up to four inhalations bid if asthma worsened for a maximum of 14 days; stepping down to two inha…

AdultMalePulmonary and Respiratory MedicineBudesonidemedicine.drug_classDrug Administration ScheduleFormoterol FumarateBronchodilatormedicineHumansPharmacology (medical)DosingBudesonideathma; therapy; guidelinesAsthmaDose-Response Relationship DrugInhalationbusiness.industryNebulizers and VaporizersInhalerBiochemistry (medical)medicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaDrug Therapy CombinationFemaleFormoterolbusinessmedicine.drugPulmonary Pharmacology & Therapeutics
researchProduct

Budesonide increases TLR4 and TLR2 expression in Treg lymphocytes of allergic asthmatics

2015

Abstract Background Reduced innate immunity responses as well as reduced T regulatory activities characterise bronchial asthma. Objectives In this study the effect of budesonide on the expression of TLR4 and TLR2 in T regulatory lymphocyte sub-population was assessed. Methods TLR4 and TLR2 expression in total peripheral blood mononuclear cells (PBMC), in CD4+/CD25+ and in CD4+/CD25− was evaluated, by flow cytometric analysis, in mild intermittent asthmatics (n = 14) and in controls (n = 11). The in vitro effects of budesonide in modulating: TLR4 and TLR2 expression in controls and in asthmatics; IL-10 expression and cytokine release (IL-6 and TNF-α selected by a multiplex assay) in asthmati…

AdultMalePulmonary and Respiratory MedicineBudesonidemedicine.medical_treatmentLymphocyteIn Vitro TechniquesCorticosteroids; Immunoregulation; T lymphocytes; TLR; Adult; Asthma; Budesonide; Cytokines; Female; Flow Cytometry; Glucocorticoids; Humans; In Vitro Techniques; Interleukin-10; Leukocytes Mononuclear; Male; T-Lymphocytes Regulatory; Toll-Like Receptor 2; Toll-Like Receptor 4; Young Adult; Pulmonary and Respiratory Medicine; Pharmacology (medical); Biochemistry (medical); Medicine (all)T-Lymphocytes RegulatoryPeripheral blood mononuclear cellYoung AdultGlucocorticoidTLRT lymphocytemedicineCorticosteroidHumansPharmacology (medical)IL-2 receptorBudesonideCytokineGlucocorticoidsIn Vitro Techniquebusiness.industryMedicine (all)Biochemistry (medical)ImmunoregulationFlow CytometryAsthmaToll-Like Receptor 2Interleukin-10Toll-Like Receptor 4Interleukin 10TLR2Cytokinemedicine.anatomical_structureImmunologyLeukocytes MononuclearTLR4CytokinesFemalebusinessHumanmedicine.drugPulmonary Pharmacology & Therapeutics
researchProduct

Treatment Monitoring Program for Implementation of Adherence to Second-Line Erlotinib for Advanced Non–Small-Cell Lung Cancer

2012

Abstract Background Adherence to erlotinib could be a determinant for clinical outcome and treatment toxicity in patients with advanced non–small-cell lung cancer (A-NSCLC). Patients and Methods In an observational study, the Basel Assessment of Adherence Scale (BAAS), a visual analogue scale (VAS), pill counting, and missed appointment rate were used to evaluate adherence in a first cohort of patients who was prescribed erlotinib without a specifically designed management strategy and in a second cohort of patients followed by an oral treatment monitoring program. Results Adherence > 95% by BAAS at 2 months of treatment in the first and second cohorts was 72% and 84%, respectively ( P = .0…

AdultMalePulmonary and Respiratory MedicineCancer Researchmedicine.medical_specialtyLung NeoplasmsVisual analogue scaleAdenocarcinomaMedication AdherenceErlotinib HydrochlorideCarcinoma Non-Small-Cell LungInternal medicinemedicineHumansErlotinib HydrochlorideProtein Kinase InhibitorsSurvival rateAgedNeoplasm StagingRetrospective StudiesAged 80 and overSalvage Therapybusiness.industryHealth Plan ImplementationRetrospective cohort studyAdenocarcinoma Bronchiolo-AlveolarMiddle AgedPrognosisSmall Cell Lung CarcinomaMonitoring programConfidence intervalSurgerySurvival RateOncologyCohortQuinazolinesCarcinoma Large CellPatient ComplianceFemaleErlotinibDrug MonitoringbusinessFollow-Up Studiesmedicine.drugClinical Lung Cancer
researchProduct

Spontaneous interleukin 2 release of bronchoalveolar lavage cells in sarcoidosis is a codeterminator of prognosis

1996

There is mounting evidence that activated interleukin 2 (IL-2)-releasing lymphocytes play a central role in the immunopathogenesis of sarcoidosis by directing inflammatory reactions and granuloma formation. In the context that a significant proportion of these cells accumulates in the lung and releases mediators, we hypothesized that different immunologically defined stages of sarcoidosis can be identified. A cohort of 89 sarcoidosis patients was allocated to four groups according to the following criteria: stage A, a low number of bronchoalveolar lavage (BAL) lymphocytes (20%) without IL-2 release (1 unit/ml in BAL cell culture supernatant); stage B, BAL lymphocytes20%, with IL-2 release (…

AdultMalePulmonary and Respiratory MedicineInterleukin 2T-LymphocytesContext (language use)InflammationStatistics NonparametricPulmonary function testingSarcoidosis PulmonarymedicineHumansCells CulturedChi-Square DistributionLungmedicine.diagnostic_testbusiness.industryrespiratory systemPrognosismedicine.diseaserespiratory tract diseasesBronchoalveolar lavagemedicine.anatomical_structureImmunologyInterleukin-2FemaleSarcoidosismedicine.symptombusinessBronchoalveolar Lavage FluidProgressive diseaseFollow-Up Studiesmedicine.drugLung
researchProduct

Extracellular matrix composition in COPD

2012

Extracellular matrix (ECM) composition has an important role in determining airway structure. We postulated that ECM lung composition of chronic obstructive pulmonary disease (COPD) patients differs from that observed in smoking and nonsmoking subjects without airflow obstruction. We determined the fractional areas of elastic fibres, type-I, -III and -IV collagen, versican, decorin, biglycan, lumican, fibronectin and tenascin in different compartments of the large and small airways and lung parenchyma in 26 COPD patients, 26 smokers without COPD and 16 nonsmoking control subjects. The fractional area of elastic fibres was higher in non-obstructed smokers than in COPD and nonsmoking controls…

AdultMalePulmonary and Respiratory MedicineLumicanPathologymedicine.medical_specialtyDecorinLumicanTenascinSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary Disease Chronic ObstructiveBiglycanParenchymamedicineHumansCOPDLungAgedCOPDLungbiologybusiness.industryBiglycanSmokingTenascinMiddle Agedrespiratory systemmedicine.diseaseImmunohistochemistryExtracellular MatrixFibronectinsRespiratory Function Testsrespiratory tract diseasesmedicine.anatomical_structureChondroitin Sulfate ProteoglycansKeratan SulfateCase-Control Studiesbiology.proteinVersicanFemaleCollagenDecorinbusiness
researchProduct

High-Resolution Computed Tomographic Evaluation of Airway Distensibility and the Effects of Lung Inflation on Airway Caliber in Healthy Subjects and …

2001

The effects of a deep inspiration (DI) in individuals with asthma differ from those observed in healthy subjects. It has been postulated that the beneficial effect of lung inflation is mediated by airway stretch. One hypothesis to explain the defects in the function of lung inflation in asthma is that a DI may be unable to stretch the airways. This may result from attenuation of the tethering forces between the airways and the surrounding parenchyma. In the current study, we used high-resolution computed tomography (HRCT) to examine the ability of a DI to distend the airways of subjects with asthma (n = 10) compared with healthy subjects (n = 9) at baseline and after increasing airway tone …

AdultMalePulmonary and Respiratory MedicineLung Volume MeasurementSettore MED/10 - Malattie Dell'Apparato RespiratorioCritical Care and Intensive Care MedicineBronchial Provocation TestsAirway resistanceReference ValuesBronchodilationmedicineHumansReference ValueLungMethacholine ChlorideProbabilityRespiratory Function TestAsthmaRespiratory Mechanicbusiness.industryAirway ResistanceRespiratory diseaserespiratory systemmedicine.diseaseAsthmaRespiratory Function Testsrespiratory tract diseasesPulmonary AlveoliBronchial Provocation TestBronchodilatationAnesthesiaRespiratory MechanicsFemaleBronchoconstrictionMethacholinemedicine.symptomLung Volume MeasurementsTomography X-Ray ComputedbusinessAirwayHumanmedicine.drugAmerican Journal of Respiratory and Critical Care Medicine
researchProduct